SGEN - Seattle Genetics, Inc.
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 175.53 |
| Open | 176.79 |
| Bid | 177.67 x 1000 |
| Ask | 177.88 x 1800 |
| Day's Range | 176.79 - 180.94 |
| 52 Week Range | 63.02 - 180.94 |
| Volume | 420,440 |
| Avg. Volume | 1,316,216 |
| Market Cap | 30.713B |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.86 |
| Earnings Date | Jul 14, 2020 - Jul 20, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 165.35 |
Fair Value
Related Research
- Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2020 financial results on Thursday, July 30, 2020 after the close of financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
- Zacks
Seattle Genetics' Adcetris Progresses Well Amid Competition
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. Further, label expansions of the drug should continue to boost the top line.
- Motley Fool
Why Seattle Genetics Shares Climbed 48.7% in the First Half
Seattle Genetics (NASDAQ: SGEN) shares rose 48.7% in the first half, according to data provided by S&P Global Market Intelligence, after the company gained U.S. regulatory approval for its second drug in less than six months. The U.S. Food and Drug Administration in April approved Tukysa for patients with metastatic HER2-positive breast cancer after approving Padcev in December for locally advanced or metastatic urothelial cancer. Urothelial cancer is the most common form of bladder cancer, and according to Grand View Research, the global drug market for the disease is growing at a 22.9% compound annual growth rate and is set to reach $3.6 billion by 2023.
- Business Wire
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive topline results from the phase 2 single-arm clinical trial known as innovaTV 204 evaluating tisotumab vedotin administered every three weeks for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer. Results from the trial showed a 24 percent confirmed objective response rate (ORR) by independent central review [95% Confidence Interval: 15.9%-33.3%] with a median duration of response (DOR) of 8.3 months. The most common treatment-related adverse events (greater than or equal to 20 percent) included alopecia, epistaxis (nose bleeds), nausea, conjunctivitis, fatigue and dry eye. The data will be submitted for presentation at an upcoming medical meeting.
- Thomson Reuters StreetEvents
Edited Transcript of SGEN.OQ earnings conference call or presentation 30-Apr-20 8:30pm GMT
Q1 2020 Seattle Genetics Inc Earnings Call
- TheStreet.com
Here's My Take on Seattle Genetics
The firm is obviously fast becoming a real player in creating treatment for certain cancers. The firm still loses money.
- Investor's Business Daily
Dow Jones Futures Slash Losses: Stock Market Rally Faces Coronavirus Wave; Apple WWDC, Tesla News In Focus
After a strong week, can the coronavirus stock market rally handle a new Covid-19 wave? Apple WWDC is on tap. Tesla is in focus. Vertex, Regeneron, Wingstop are new buys.
- Business Wire
Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in a phase 1 clinical trial evaluating investigational agent SEA-TGT, also known as SGN-TGT, an anti-TIGIT antibody for patients with solid tumors and lymphomas. TIGIT (T-cell immune receptor with Ig and ITIM domains) is an inhibitory immune receptor that is emerging as a clinically relevant immuno-oncology target. SEA-TGT is a nonfucosylated human IgG1 antibody that uses the Company’s proprietary Sugar Engineered Antibody (SEA) technology. The Company also announced the dosing of the first patient in a phase 1 clinical trial evaluating investigational agent SGN-B6A, an antibody-drug conjugate (ADC) targeting integrin beta-6, which is overexpressed in numerous solid tumors and has been demonstrated to be a negative prognostic indicator across a diverse range of cancers.
- Insider Monkey
Do Hedge Funds Love Seattle Genetics, Inc. (SGEN)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
- Business Wire
Seattle Genetics to Present at Goldman Sachs 41st Annual Global Healthcare Conference
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the virtual Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 11:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.
- Zacks
Why Is Seattle Genetics (SGEN) Up 14.6% Since Last Earnings Report?
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
Seattle Genetics Announces Positive Results from Exploratory Analyses of HER2CLIMB for TUKYSAâ„¢ (tucatinib) in Brain Metastases Patients With HER2-Positive Breast Cancer
Seattle Genetics, Inc. today announced positive results from exploratory analyses of intracranial efficacy, including survival, in patients with HER2-positive metastatic breast cancer (MBC) who had stable or active brain metastases in the HER2CLIMB pivotal trial of TUKYSAâ„¢ (tucatinib). HER2CLIMB compared TUKYSA in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with unresectable, locally advanced or metastatic HER2-positive breast cancer with or without brain metastases. Of the patients enrolled in the trial, 48 percent had a presence or history of brain metastases. Results demonstrated that the addition of TUKYSA to trastuzumab and capecitabine in patients with brain metastases delayed progression in the brain, doubled the intracranial response rate (tumor shrinkage in the brain) and reduced the overall risk of death by nearly half. The data were consistent across patients who had either stable or active brain metastases. Results were presented in an oral presentation in the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the Journal of Clinical Oncology.
- Barrons.com
Anterix and Bausch Holding See Activist Action
Owl Creek Asset Management increased its stake in wireless-communications firm Anterix, while Paulson & Co. bought more Bausch stock.
- Zacks
Seattle Genetics' Adcetris Label Expands in EU for Lymphoma
Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.
- Zacks
Nasdaq ETF (QQQ) Joins $100 Billion Club: 10 Stock Winners
Invesco QQQ (QQQ), which tracks the Nasdaq 100 Index, joined the $100 billion club of AUM last week.
- Business Wire
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the current conditional marketing authorization for ADCETRIS® (brentuximab vedotin) to include treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL), in combination with CHP (cyclophosphamide, doxorubicin, prednisone). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on the surface of several types of peripheral T-cell lymphomas (PTCL), including sALCL. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on March 27, 2020.
- Business Wire
Seattle Genetics Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the presentation of new data from its expanding pipeline of marketed and investigational therapies in the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 29-31. Thirteen abstracts — including an oral presentation of new data from patients with brain metastases who were part of the pivotal HER2CLIMB trial of TUKYSA™ (tucatinib) in patients with previously treated HER2-positive metastatic breast cancer — will highlight the company’s continued progress in advancing research in cancers that have a significant unmet need.
- Business Wire
Seattle Genetics Announces the Approval of TUKYSAâ„¢ (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA™ (tucatinib) tablets in combination with trastuzumab and capecitabine, for the treatment of patients with metastatic HER2-positive breast cancer, who have previously received two or more anti-HER2 regimens in any setting, including trastuzumab, pertuzumab and trastuzumab-emtansine (T–DM1).
- Zacks
Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected
Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
- GuruFocus.com
Analysts See Seattle Genetics Profitable in 2022
Biotech’s shares up more than 140% in past year Continue reading...
- Zacks
Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses
Allogene (ALLO) reports no revenues for the first quarter of 2020.
- Simply Wall St.
Industry Analysts Just Upgraded Their Seattle Genetics, Inc. (NASDAQ:SGEN) Revenue Forecasts By 10%
Celebrations may be in order for Seattle Genetics, Inc. (NASDAQ:SGEN) shareholders, with the analysts delivering a...
- Business Wire
Seattle Genetics to Present at the BofA Securities Virtual Health Care Conference 2020
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the BofA Securities Virtual Health Care Conference 2020 on Tuesday, May 12, 2020 at 11:40 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.
- Zacks
Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales
Seattle Genetics (SGEN) reports narrower-than-expected loss in Q1 while revenues beat estimates.
- TheStreet.com
Seattle Genetics Soars on Cancer Drugs: Here's How to Play the Stock
On Mad Money Friday night, Jim Cramer checked in Dr. Clay Siegall, chairman and CEO of Seattle Genetics Inc. , a biotech on the front lines of oncology. Siegall said their drug for metastatic bladder cancer is in its first full quarter of sales and doctors are embracing it as the leading treatment. Siegall was also bullish on Tukysa, the company's breast cancer treatment, which received FDA approval this month for advanced-stage HER2-positive breast cancer.
